Overview

Effect of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy in High Risk Nasopharyngeal Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The investigators aim to evaluate the survival benefit from triple combination of induction, concurrent and aduvant chemotherapy versus concurrent chemotherapy alone for high risk locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.

Phase:

Phase 3

Details

Lead Sponsor:

Sun Yat-sen University

Collaborators:

Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Affiliated Tumor Hospital of Guangzhou Medical University
The First Affiliated Hospital of Guangdong Pharmaceutical University
The First Affiliated Hospital of Guangzhou Medical University

Treatments:

Capecitabine
Cisplatin
Docetaxel